Default company panoramic image

GlycoMira Therapeutics Inc.

GlycoMira Therapeutics is a development-stage company with potent and patented inflammation-modulating compounds and experienced management.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Salt Lake City, UT, USA
  • Currency USD
  • Founded July 2008
  • Employees 5
  • Website

Company Summary

GTI has developed agents with potential to treat interstitial cystitis (IC), a chronic and debilitating condition. GM-0111, our lead compound, provides an effective new treatment. Current options to treat IC are limited, so urologists are eager for better options. Support groups for IC patients promote new options through social media, making them important customers. The economic impact of IC is large, so third party payers are key stakeholders.


  • Default avatar
    Tom Heath

    Thomas Heath, M.B.A. is the President and CEO of GlycoMira Therapeutics. Before joining GlycoMira, Tom Heath served as Senior Vice President at NPS Pharmaceutials. He was a Founder-Director-President at Echelon Biosciences and also was Pharmaceutical Division Manager at Pfizer (Montreal, Canada). Mr. Heath received his MBA from the David Eccles School of Business at the University of Utah.

  • Default avatar
    Glenn Prestwich
    Chief Science Officer

    A co-founder of GlycoMira Therapeutics, Dr. Glenn Prestwich, Ph.D. is Presidential Professor of Medicinal Chemistry and Presidential Special Assistant for Faculty Entrepreneurism at the University of Utah. Dr. Prestwich’s research interests are hyaluronan derivatives for tissue engineering and reparative medicine, lipid signaling, and anti-inflammatory therapeutic compounds. He has received numerous awards for his contributions to science and tec

  • Default avatar
    Tom Kennedy
    Chief Medical Officer

    A co-founder of GlycoMira Therapeutics, Dr. Tom Kennedy, M.D. is a Professor of Medicine at Georgia Regents University School of Medicine. Dr. Kennedy’s research interests are biomedical applications of heparinoid compounds to treat human diseases. He is one of our major driving forces in research and development.
    Previously, Dr. Kennedy was Professor of Medicine at the University of Utah. He received his medical training at Vanderbilt

  • Default avatar
    Justin Savage
    Director of Operations

    Justin R. Savage, Ph.D. is Director of Operations for GlycoMira Therapeutics, Inc. and has been with the Company since 2009. Dr. Savage has over 10 years of experience in proteomics and drug development.
    Dr. Savage received his B.A. degree in chemistry from Southern Utah University and his Ph.D. in Biochemistry from Brigham Young University.